Caas Capital Management LP Zentalis Pharmaceuticals, Inc. Transaction History

Caas Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $2.34 Million - $3.68 Million	-50,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $1.87 Million - $3.11 Million	50,000 New	50,000 $2.66 Million
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $4.73 Million - $6.99 Million	-132,642 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $2.07 Million - $3.79 Million	65,311 Added 97.0%	132,642 $6.89 Million
Q3 2020 Nov 09, 2020	BUY	$27.03 - $47.97 $1.14 Million - $2.03 Million	42,331 Added 169.32%	67,331 $2.2 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $580,000 - $1.37 Million	25,000 New	25,000 $1.2 Million

147

65.4M

43.2K

21.7K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $102M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.